Synlogic to Host Analyst & Investor Event at the Society for Immunotherapy of Cancer (SITC) 2018 Annual Meeting

From Startup Synlogic Tx

Link to Full Article:

– Presentations to feature key opinion leaders and expand on
preclinical data from Synlogic’s first immuno-oncology candidate,
accepted for presentation at SITC 2018 –
– Company to webcast event, beginning at 12:30 p.m. ET on Saturday,
November 10, 2018 –
CAMBRIDGE, Mass.–(BUSINESS WIRE)–Nov. 1, 2018–
Synlogic, Inc. (Nasdaq:
SYBX), a clinical stage company applying synthetic biology to
probiotics to develop novel, living medicines, today announced that the
Company will host an event for analysts and investors in conjunction
with the Society for Immunotherapy of Cancer’s 33rd Annual
Meeting * Pre-Conference Programs (SITC 2018), with formal presentations
beginning at 12:30 pm ET on November 10, 2018.

At SITC 2018, Synlogic will deliver a poster presentation of preclinical
data for its innate immune activator candidate. Details about the poster
presentation and abstract are below:

Title: Development of a STING Agonist-producing Synthetic
Biotic™ Medicine to Activate Innate and Adaptive Immunity and Drive
Antitumor Immune Responses

Abstract ID: P624

Location: Poster Hall Location: Hall E

Time:Friday, Nov. 9 from 8:00 am– 8:00 pm ET and Saturday,
Nov. 10 from 8:00 am – 8:30 pm ET

The analyst and investor event will expand on these data to highlight
the potential of Synlogic’s Synthetic Biotic platform in
immuno-oncology, with featured speakers including:

Synlogic management

Filip Janku, MD, PhD; MD Anderson Cancer Center
Dmitriy Zamarin, MD, PhD; Memorial Sloan Kettering Cancer Center

A live webcast of the presentation and accompanying slides will be
available under “Events
and Presentations” in the News & Investors section of the
Company’s website at
An archived webcast recording of the event will be available on the
website for approximately 30 days.

About SynlogicSynlogic is pioneering the development of a
novel class of living medicines, Synthetic Biotic medicines, based on
its proprietary drug development platform. Synlogic leverages the tools
and principles of synthetic biology to genetically engineer probiotic
microbes to perform or deliver critical functions missing or damaged due
to disease. The company’s two lead programs, SYNB1020 and SYNB1618,
target hyperammonemia as a result of liver damage or genetic disease,
and PKU, respectively. When delivered orally, Synthetic Biotic medicines
can act from the gut to compensate for the dysfunctional metabolic
pathway and have a systemic effect, with the potential to significantly
improve symptoms of disease for affected patients. In addition, the
company is leveraging the broad potential of its platform to create
Synthetic Biotic medicines for the treatment of more common diseases,
including liver disease, inflammatory and immune disorders, and cancer.
Synlogic is collaborating with AbbVie to develop Synthetic Biotic-based
treatments for inflammatory bowel disease (IBD). For more information,
please visit

Forward-Looking StatementsThis press release contains
“forward-looking statements” that involve substantial risks and
uncertainties for purposes of the safe harbor provided by the Private
Securities Litigation Reform Act of 1995. All statements, other than
statements of historical facts, included in this press release regarding
strategy, future operations, future financial position, future revenue,
projected expenses, prospects, plans and objectives of management are
forward-looking statements. In addition, when or if used in this press
release, the words “may,” “could,” “should,” “anticipate,” “believe,”
“estimate,” “expect,” “intend,” “plan,” “predict” and similar
expressions and their variants, as they relate to Synlogic may identify
forward-looking statements. Examples of forward-looking statements,
include, but are not limited to, statements regarding the potential of
Synlogic’s platform to develop therapeutics to address a wide range of
diseases including: inborn errors of metabolism, liver disease,
inflammatory and immune disorders, and cancer; the future clinical
development of Synthetic Biotic medicines; the approach Synlogic is
taking to discover and develop novel therapeutics using synthetic
biology; the potential of Synlogic’s technology to treat hyperammonemia
and phenylketonuria; and the expected timing of Synlogic’s anticipated
clinical trial initiations. Actual results could differ materially from
those contained in any forward-looking statement as a result of various
factors, including: the uncertainties inherent in the preclinical
development process; the ability of Synlogic to protect its intellectual
property rights; and legislative, regulatory, political and economic
developments, as well as those risks identified under the heading “Risk
Factors” in Synlogic’s filings with the SEC. The forward-looking
statements contained in this press release reflect Synlogic’s current
views with respect to future events. Synlogic anticipates that
subsequent events and developments will cause its views to change.
However, while Synlogic may elect to update these forward-looking
statements in the future, Synlogic specifically disclaims any obligation
to do so. These forward-looking statements should not be relied upon as
representing Synlogic’s view as of any date subsequent to the date

View source version on
Source: Synlogic, Inc.
MEDIA CONTACT:SynlogicCourtney Heath,
CONTACT:SynlogicElizabeth Wolffe, Ph.D.,

Please visit their site for more information: Synlogic

All,Biotechnology,Healthcare News
2018-11-02 04:33:33